anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The goal of this study is to determine the relationship of apoprotein A-1 (apoA-I) glycation and development of diabetic atherosclerosis.

ApoA-I is crucial for reverse cholesterol transport and anti-inflammation/anti-atherosclersis functions of HDL. However, apoA-I is easily subjected to non-enzymatic glycation modification in diabetic milleu. Our preliminary study has shown that apoA-I in HDL from type 2 diabetes mellitus (T2DM) patients with coronary artery disease (CAD) is significantly glycated, and site specific glycation of apoA-I impairs HDL function and is related to the severity of atherosclerosis. To the best of our knowledge, less clinical information regarding apoA-I glycation and CAD has been reported. In this cross-sectional study, we will consecutively enroll several hundred diabetic patients (two to three hundred) with no CAD (less than stenosis of 25% in coronary CTA) as controls. And we will also consecutively enroll several hundred (six to eight hundred) angiographically established T2DM patients with CAD (stenosis of \>50% in coronary angiography). Serum HDL of all participants will be isolated and a qualitative and quantitative proteomic analysis of apoA-I glycation will be performed by mass spectrometry. The relation of apoA-I glycaiton and HDL function and angioraphy-determined severity of CAD will be evaluated. Later, we will follow these diabetic patients for approximately two years to analyze the influence of apoA-I glycation on the clinical outcomes (stroke, myocardial infarction, hospitalization for heart failure, death due to cardiovascular causes, etc) including plaque progression.
Patients, their families and their caregivers should be encouraged to be alert to the emergence of anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, (psychomotor restlessness), hypomania, mania, other unusual changes in behavior, worsening of depression, and suicidal ideation, especially early during antidepressant treatment and when the dose is adjusted up or down. Families and caregivers of patients should be advised to look for the emergence of such symptoms on a day-to-day basis, since changes may be abrupt. Such symptoms should be reported to the patient’s prescriber or health professional, especially if they are severe, abrupt in onset, or were not part of the patient’s presenting symptoms. Symptoms such as these may be associated with an increased risk for suicidal thinking and behavior and indicate a need for very close monitoring and possibly changes in the medication.

Because priapism has been reported to occur in patients receiving trazodone HCl, patients with prolonged or inappropriate penile erection should immediately discontinue the drug and consult with the physician (see WARNINGS).

Antidepressants may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks, such as operating an automobile or machinery; the patient should be cautioned accordingly.

Trazodone HCl may enhance the response to alcohol, barbiturates, and other CNS depressants.

Trazodone HCl should be given shortly after a meal or light snack. Within any individual patient, total drug absorption may be up to 20% higher when the drug is taken with food rather than on an empty stomach. The risk of dizziness/lightheadedness may increase under fasting conditions.
PURPOSE: Tinnitus is a condition that causes people to hear sounds without an external source. One significant issue arising from this condition is the difficulty in communicating, especially in the presence of noisy backgrounds. The process of understanding speech in challenging situations requires both cognitive and auditory abilities. Since tinnitus presents unique challenges, it is important to investigate how it affects speech perception in noise.
METHOD: In this review, 32 articles were investigated to determine the effect of tinnitus on the effect of speech in noise perception performance. Based on the meta-analysis performed using a random-effects model, meta-regression was used to explore the moderating effects of age and hearing acuity.
RESULTS: A total of 32 studies were reviewed, and the results of the meta-analysis revealed that tinnitus significantly impacts speech in terms of noise perception performance. Additionally, the regression analysis revealed that age and hearing acuity are not significant predictors of speech in noise perception.
CONCLUSION: Our findings suggest that tinnitus affects speech perception in noisy environments due to cognitive impairments and central auditory processing deficits. Hearing loss and aging also contribute to reduced speech in noise performance. Interventions and further research are necessary to address individual challenges associated with continuous subjective tinnitus.
Levofloxacin concentration in plasma was measured in 14 healthy adult volunteers during a 16-day course of treatment with levofloxacin ophthalmic solution. The dosing schedule was 1 to 2 drops per eye once in the morning on Days 1 and 16; 1 to 2 drops per eye every two hours Days 2 through 8; and 1 to 2 per eye every four hours Days 9 through 15. The mean levofloxacin concentration in plasma 1 hour post dose ranged from 3.13 ng/mL on Day 1 to 10.4 ng/mL on Day 16.

Maximum mean levofloxacin concentrations increased from 3.22 ng/mL on Day 1 to 10.9 ng/mL on Day 16, which is more than 400 times lower than those reported after standard oral doses of levofloxacin.

Levofloxacin concentration in tears was measured in 100 healthy adult volunteers at various time points following instillation of 2 drops of levofloxacin ophthalmic solution. Mean tear concentration measured 15 minutes after instillation was 757 mcg/mL.
The invention discloses a method, a system and a device for identifying a medicine-disease relation. The method comprises the steps of obtaining a two-dimensional matrix and/or a gray-scale map of a disease relation corresponding to a drug-disease relation pair to be identified, and inputting the two-dimensional matrix and/or the gray-scale map into a convolutional neural network for processing to obtain an identification result. The system comprises an acquisition module for acquiring the drug-disease relation two-dimensional matrix and/or the gray scale map, and a processing module for inputting the drug-disease relation two-dimensional matrix and/or the gray scale map into the convolutional neural network for processing so as to output a recognition result. The apparatus includes a memory storing at least one program and a processor executing the at least one program. The invention utilizes the processing function of the convolutional neural network to quickly and efficiently identify the drug-disease treatment relationship, identify the potential drug-disease interaction and develop the lead compound identification and drug relocation research. The invention is widely applied to the field of computer-aided drug design.
The invention provides a learning system, a rehabilitation support system, a method, a program and a learning completion model. The learning unit of the learning system generates the following learning model. That is, the learning model is a model to which rehabilitation data for each predetermined period regarding rehabilitation exercises performed by the trainer using the rehabilitation support system is input to predict changes in the setting parameters. The setting parameter is a setting parameter in the rehabilitation assisting system when the trainer carries out rehabilitation. The rehabilitation data at least includes index data representing at least one of a symptom, physical ability, and degree of recovery of the trainer, trainer data representing a feature of the trainer, and training data including setting parameters. The learning unit generates a learning model using data until the index data reaches a predetermined target level as teaching data.
Women will be admitted when active phase of labour starts defined as the presence of at least three regular uterine contractions over 10 minutes with cervical dilatation four centimeters with cervical effacement not less than 50% and no progress of labor for 2 hours or more.

Amniotomy was done in those with intact membrane and continuous electronic fetal monitoring was done. Women with prolonged labor after these measures were randomly divided using automated web-based randomization system into 2 equal groups. Group I included 50 women received 40mg HBB (Buscopan, Memphis Co, Giza, Egypt) intravenous bolus injection. Group II included 50 women received 2 ml of normal saline. The obstetrician, participants and outcome assessor were all blinded to the group assignment. Labor will be monitored by Vaginal examination every two hours. The duration of the first stage was calculated from the time of cervical dilatation of three to four centimeters in active labor until a fully dilated cervix was observed.
This group will receive no intervention to train the specificity of autobiographical memories. During two weeks (from Day 0 to Day 15), participants will complete continuous assessments (i.e. once a day) to monitor their positive and negative affect.
Cerebrospinal fluid opening pressure values are associated with various neurologic diseases; however, numerous factors can modify this measurement. This study aims to describe factors related to modifications in opening pressure measurements in pediatric patients. Methods: A retrospective analysis of lumbar punctures in pediatric patients conducted by the neuropediatrics group with institutional standardization. Bivariate and linear regression analyses were performed to determine the association between opening pressure and variables included in the study. Results: 544 events, median age 107 months, median opening pressure 19.7 cm H2O. Bivariate analysis found no association with medication use; anesthetics that increased opening pressure were remifentanil (P = .02) and propofol (P = .05), along with a positive linear correlation between opening pressure and age (P < .0001). Multiple linear regression analysis revealed that age, BMI, male gender, and remifentanil use were associated with an increase in opening pressure, whereas corticosteroid withdrawal was associated with a reduction in opening pressure. There is an interaction between age and headache, with an association with increased opening pressure up to around 140 months. Conclusion: This study identifies factors associated with changes in opening pressure, crucial for estimating normal opening pressure values in children. Headaches, anesthetic use, and corticosteroid withdrawal are confirmed as significant factors.
Four multicenter, open-label, two-period crossover studies were conducted to compare the pharmacodynamic effects of esomeprazole following intravenous or oral administration on acid suppression in 206 patients with symptoms of GERD with or without erosive esophagitis. Patients were randomized to receive either 20 or 40 mg of NEXIUM I.V. or oral esomeprazole once daily for 10 days (Period 1), and then were switched in Period 2 to the other formulation for 10 days, matching their respective dose from Period 1. NEXIUM I.V. 20 mg and 40 mg was administered as a 3-minute injection in two of the studies and as a 15-minute infusion in the other two studies.

The patient population ranged from 18 to 72 years old; 54% were female; 53% Caucasian, 24% Black, 5% Asian, and 17% other race. Basal acid output (BAO) and maximal acid output (MAO) were determined 22 to 24 hours post-dose on Period 1, Day 11; on Period 2, Day 3; and on Period 2, Day 11. BAO and MAO were estimated from 1-hour continuous collections of gastric contents prior to and following (respectively) subcutaneous injection of 6.0 mcg/kg of pentagastrin.

In these studies, after 10 days of once daily administration, NEXIUM I.V. 20 mg and 40 mg were similar to the corresponding oral dosage of esomeprazole in their ability to suppress BAO and MAO in these GERD patients (see Table 9 below).

There were no major changes in acid suppression when switching between intravenous and oral dosage forms.
A method for ocular simulated camera assisted robot training is provided. In some implementations, the method includes initializing, by a processor, a robotics assembly. The method further includes connecting, by the processor, to one or more computing devices. The method further includes operating, by the processor, the robotics assembly. The method further includes simulating, by the processor, an eye movement of a human or animal. The method further includes operating, by the processor, a laser to perform a determined exercise on an eye of the robotics assembly. Related systems, methods, and articles of manufacture are also described.
Evaluation parameters will be performed to the patients. Physical activity level, exercise barriers, disease activity, fatigue, depression, pain, sleep disorders, aerobic capacity and quality of life will be assessed using International Physical Activity Questionnaire-Short Form (IPAQ),Exercise Benefits/Barriers Scale, Behçet Disease Current Activity Form (BDCAF), Fatigue Severity Scale (FSS), Beck Depression Inventory (BDI), McGill Pain Questionnaire- Short Form (MPQ-SF), Pittsburgh Sleep Quality Index, 6 minute walk test and Behçet's Disease Quality of Life Questionnaire, respectively.
Randomization of a total of approx. 100 subjects to one of two treatment arms at 1:1 ratio to receive 5 µg of the RRV Vaccine with/without adjuvant (Al(OH)3). Vaccinations take place upon review of Cohort 1a Day 7 safety data by DMC and recommendation to proceed. Booster vaccination to follow 180 days after first vaccination.
ABSTRACT           Apparatus for accumulating stacks of superimposed layers or piles of paper sheets has a horizontal platform which receives successive layers from a feeding unit and can open up to permit the properly oriented layer thereon to descend by gravity onto an elevator which is disposed at a level below the platform and at a distance only slightly exceeding the height of a layer.  The elevator is then lowered by a step, and the platform receives and discharges the next layer in the same way so that the elevator supports two layers.  The accumulation of layers on the elevator is repeated as often as desired in order to accumulate a stack of desired height.  The elevator is then opened and permits the fully grown stack to descend through a chute and into a container (such as a carton which is disposed therebelow and is properly centered by a suitable receptacle).  The descent of the stack is braked by the column of air which is pushed by the stack in front of it through the chute and into the interior of the carton.  The platform comprises two panels which are movable laterally away from each other to permit a layer to descend from the platform onto the elevator or onto the topmost layer on the elevator.
Patients in EARW group drink EARW (pH 9.5) 10 mL/kg body weight per a day using experimental device installed in the house for 6 weeks. We recommend to drink water in empty stomach three or four times a day. The water generated from device will be administered immediately, not to be stored.
Treatment options for CTCL include both skin-directed and systemic therapies. Topical treatments are effective for early-stage disease that is localized to the skin. However, disease involving the lymph nodes or visceral sites can be palliated but rarely cured, even with the most aggressive regimens of systemic chemotherapy. Unfortunately, current treatment options at this stage only provide a short term response. Thus, it is important that additional therapies are investigated to manage this malignancy.

Bexarotene has been approved by the FDA for the treatment of Cutaneous T-Cell Lymphoma (CTCL).Bexarotene binds the RXR(Retinoid X Receptor)inside the cell, a receptor that forms heterodimers with a multitude of other nuclear receptors. One of these is the PPARγ (Peroxisome Proliferator Activator Receptor Gamma), a nuclear receptor that binds Rosiglitazone.Rosiglitazone is an FDA approved antidiabetic agent of the Thiazolidinedione class. Rosiglitazone increases insulin sensitivity and is useful in the treatment of type 2 diabetes. In vitro data suggest that rosiglitazone and bexarotene may act synergistically to induce apoptosis in cell lines derived from patients with cutaneous T cell lymphoma (CTCL). This pilot study will investigate this possible synergism in a small cohort of patients with stable or progressive CTCL already being treated with bexarotene.
PROBLEM TO BE SOLVED: To prepare a hair grower capable of manifesting excellent hair-tonic activities and depilation-preventing activities by formulating extract of carpophore or mycelium of Hericium coralloides. SOLUTION: This cosmetic contains an extraction fraction obtained by extracting water-insoluble residue of carpophore or mycelium of Hericium coralloides with an organic solvent. The extraction fraction is obtained, for example, by inoculating a spawn of the Hericium coralloides (the genus Hericium) in a medium or the like constituted of an yeast extract, a glucose and the like and having pH 5.5, aerobically culturing the inoculated spawn while stirring at 25 deg.C, freeze-drying and pulverizing the obtained mycelium, subjecting the pulverized material to a treatment such as homogenization, subjecting the treated material to centrifugal separation to provide an extraction residue, and extracting the extraction residue with an organic solvent (e.g. ethanol and acetone).  The formulating amount of the extraction fraction is preferably 0.0001-20.0 wt.% based on the whole amount of the cosmetic. The cosmetic can includes a vitamin E derivative, a pantothenic acid derivative or the like formulated therewith.
Surgical site infections (SSIs) are among the most clinically relevant complications and the use of prophylactic cefazolin is common practice. However, the knowledge about the pharmacological aspects of prophylactic cefazolin in the lower extremities remains limited. In this prospective cohort, a sub-study of the WIFI-2 randomized controlled trial, adults between 18 and 75 years of age who were scheduled for implant removal below the level of the knee and randomized for cefazolin, was included. A maximum of two venous plasma, target-site plasma, and target-site tissue samples were taken during surgery. The primary outcomes were the cefazolin concentrations in venous plasma, target-site plasma, and target-site tissue. A total of 27 patients [median (interquartile range) age, 42 (29-59) years; 17 (63%) male] with 138 samples were included in the study. A minimum of 6 weeks follow-up was available for all patients. The mean (SD) venous plasma, target-site plasma, and target-site tissue concentrations were 36 (13) µg/mL, 29 (13) µg/mL, and 28 (13) µg/g, respectively, and the cefazolin concentrations between the different locations of surgery did not differ significantly in both target-site plasma and target-site tissue (P = 0.822 and P = 0.840). In conclusion, 2 g of prophylactic cefazolin demonstrates adequacy in maintaining coverage for a duration of at least 80 minutes of surgery below the level of the knee, significantly surpassing the MIC90 required to combat the most prevalent microorganisms. This study represents the first of its kind to assess cefazolin concentrations in the lower extremities by examining both plasma and tissue samples in this magnitude.
ATP synthase inhibitory factor subunit 1 (IF1) is an inhibitory subunit of mitochondrial ATP synthase, playing a crucial role in regulating mitochondrial respiration and energetics. It is well-established that IF1 interacts with the F1 sector of ATP synthase to inhibit the reversal rotation and, thus, ATP hydrolysis. Recent evidence supports that IF1 also inhibits forward rotation or the ATP synthesis activity. Adding to the complexity, IF1 may also facilitate mitophagy and cristae formation. The implications of these complex actions of IF1 for cellular function remain obscure. In the present study, we found that IF1 expression was markedly upregulated in hypoxic MEFs relative to normoxic MEFs. We investigate how IF1 affects cellular growth and function in cultured mouse embryonic fibroblasts derived from mouse lines with systemic IF1 overexpression and knockout under normoxia and hypoxia. Cell survival and proliferation analyses revealed that IF1 overexpression exerted limited effects on cellular viability but substantially increased proliferation under normoxia, whereas it facilitated both cellular viability and proliferation under hypoxia. The absence of IF1 may have a pro-survival effect but not a proliferative one in both normoxia and hypoxia. Cellular bioenergetic analyses revealed that IF1 suppressed cellular respiration when subjected to normoxia and was even more pronounced when subjected to hypoxia with increased mitochondrial ATP production. In contrast, IF1 knockout MEFs showed markedly increased cellular respiration under both normoxia and hypoxia with little change in mitochondrial ATP. Glycolytic stress assay revealed that IF1 overexpression modestly increased glycolysis in normoxia and hypoxia. Interestingly, the absence of IF1 in MEFs led to substantial increases in glycolysis. Therefore, we conclude that IF1 mainly inhibits cellular respiration and enhances cellular glycolysis to preserve mitochondrial ATP. On the other hand, IF1 deletion can significantly facilitate cellular respiration and glycolysis without leading to mitochondrial ATP deficit.
Oil-in-water (O/W) and water-in-oil (W/O) microemulsions of fragrance product formulations are provided. The microemulsions are clear or at least translucent, sprayable, and non-sticky. Novel combinations of anionic surfactant components (a) and hydrophilic coactives (highly water soluble component (b) or a mixture of highly water soluble (b)(i) and less water soluble polar (b)(ii) components) are used to obtain fragrance product formulations that are free or substantially free of ethanol. The anionic surfactants have a hydrophilic-lipophilic balance ("HLB") modified by the use of classes of anionic surfactant components (a) and commercially available hydrophilic component coactives ((b) or mixture of (b)(i) and (b)(ii)), not previously recognized as effective in this type of system. Highly, preferably infinitely, water soluble coactives (b) as well as mixtures of highly, preferably infinitely, water soluble coactives (b)(i) with other less water soluble polar coactives (b)(ii), modify the HLB of anionic surfactants in such a way as to enable the formation of stable, clear microemulsions of fragrance product compositions. These compositions contain lower ratios of surfactant to oil than conventional nonionic (or ionic surfactants with lipophilic coactives) aqueous or alcohol free compositions. As such, the present fragrance compositions are sprayable and nonsticky.
Embodiments described herein generally relate to systems and methods for treatments using xenon and hydrogen. In some embodiments, liquids comprising xenon and hydrogen are provided. Such liquids may be useful, for example, for the treatment of animal and human diseases, for improvement in athletic performance, for the enhancement of the overall health of a subject, or the like. The liquids (e.g., aqueous solutions) and articles described herein may be administered to a subject, e.g., drunk by a subject. Some embodiments relate to liquids disposed within a container (e.g., a sealed container), such that the liquid comprises hydrogen gas and a noble gas dissolved or otherwise contained (e.g., infused) in the liquid. In certain embodiments, the hydrogen gas and/or noble gas may be present in the liquid at a particular concentration (e.g., a physiologically relevant concentration). Advantageously, the compositions, articles, and methods described herein may provide liquids containing hydrogen gas and a noble gas that are shelf-stable (e.g., maintain a relatively stable concentration of hydrogen gas and/or noble gas(es)) for relatively long periods of time (e.g., at least 7 days).